Larysuicide: an online risk stratification system to identify patients at high risk of suicide after the laryngeal cancer diagnosis - Tu Z, Li C, Hu Q, Luo J.
In this study, we aimed to develop an online risk stratification system, named Larysuicide, to identify patients at high ri... (Source: SafetyLit)
Source: SafetyLit - February 14, 2023 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Asbestos Health Screenings in Libby, Montana, Expanding
Highly specialized asbestos exposure health screenings in Libby, Montana, have gone mobile.
In an effort to identify lung abnormalities at their earliest stage, the groundbreaking Center for Asbestos Related Disease – known as CARD – has begun touring the state, offering its services to those unable or unwilling to travel.
The efforts have been well received.
Libby is a small town in rural northwest Montana that is home to one of the largest human-made environmental disasters and longest-running asbestos cleanup project in American history.
Although restoration is all but complete in the scenic and charming...
Source: Asbestos and Mesothelioma News - September 20, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Asbestos Exposure Mesothelioma Source Type: news
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
Expert Alert: Options for laryngeal regeneration
PHOENIX, Ariz. — Mayo Clinic is using 3D printing as a new option to heal the larynx after cancer or traumatic injury. David Lott, M.D., a Mayo Clinic otolaryngologist and head and neck surgeon, is an expert who can speak about a pioneering procedure using 3D bioimplants and tissue engineering to regenerate the larynx, more commonly known as the voice box. Dr. Lott also is the associate director of the Center for Regenerative Medicine at… (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - August 2, 2022 Category: Hospital Management Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
What Are Laryngeal and Hypopharyngeal Cancers?
Title: What Are Laryngeal and Hypopharyngeal Cancers?Category: Diseases and ConditionsCreated: 3/23/2022 12:00:00 AMLast Editorial Review: 3/23/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 23, 2022 Category: Cancer & Oncology Source Type: news
This 'artificial larynx' prototype aims to give cancer survivors their own voices back
Masaki Takeuchi, a young engineer in Tokyo, Japan, is teaming up with laryngeal cancer survivors to create and test Syrinx -- a machine-learning, hands-free, wearable electrolarynx. (Source: CNN.com - Health)
Source: CNN.com - Health - March 23, 2022 Category: Consumer Health News Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Throat cancer symptoms: Key signs of cancer that affect your throat and voice
THROAT CANCER is the name sometimes given to cancers affecting the thyroid, larynx, oesophagus or trachea. What are the symptoms to look out for? (Source: Daily Express - Health)
Source: Daily Express - Health - November 29, 2021 Category: Consumer Health News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
How Long Can You Live with Larynx Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 11, 2021 Category: General Medicine Source Type: news
Is Stage 3 Larynx Cancer Curable
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 11, 2021 Category: General Medicine Source Type: news
Coffee protects against liver cancer while alcohol is linked with numerous cancers
Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer - as well as the more widely known links to breast and liver cancer - according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin. (Source: World Pharma News)
Source: World Pharma News - August 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
